Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA f...( ...),Health

MORRISTOWN, N.J., July 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative treatment of advanced prostate cancer. The TRELSTAR(R) NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies.

According to the letter, the FDA has requested clarifications related to the clinical testing of the product, additional information regarding the chemistry, manufacturing and controls (CMC) of the product and other components, and information related to third party manufacturing. Watson is working to ensure the requested information is provided to the FDA expeditiously.

TRELSTAR(R) 22.5 mg builds on Watson's long-standing track record in prostate cancer and expanding urology franchise. The new, longer-acting formulation of TRELSTAR(R) is designed to be conveniently administered and to continuously suppress the production of testosterone in men with advanced prostate cancer for 24 weeks. TRELSTAR(R) is an already proven therapy with established efficacy and safety in two formulations - a four-week formulation (TRELSTAR(R) DEPOT) and a 12-week formulation (TRELSTAR(R) LA).

About TRELSTAR(R)

TRELSTAR(R), developed by Debiopharm Group and marketed by Watson, administers a synthetic luteinizing hormone releasing hormone (LHRH) agonist, triptorelin, which suppresses the production of testosterone in the testicles. Prostatic cancer proliferation is regulated in part by
'/>"/>